Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies. (Q38790644)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921308%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

title

Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921308%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921308%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Martine Pugniere

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921308%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

10

Olivier Michielin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921308%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

author name string

Sylvie Choblet

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921308%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Justyna Iwaszkiewicz

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921308%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Pierre Cérutti

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921308%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Annick Ozil

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921308%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Séverine Loisel

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921308%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Greta Ubiali

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921308%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Vincent Zoete

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921308%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Christian Berthou

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921308%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Jean Kadouche

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921308%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Jean-Pierre Mach

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921308%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Martine Duonor-Cérutti

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921308%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

language of work or name

English

0 references

publication date

26 February 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921308%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

published in

Journal of Immunology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921308%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

196

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921308%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921308%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

3199-3211

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921308%20AND%20SRC:MED&resulttype=core&format=json

Antibody therapeutics in cancer.

9 March 2020

cites work

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Maturing antibody-drug conjugate pipeline hits 30.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Tumor-antigen-binding bispecific antibodies for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Alternative molecular formats and therapeutic applications for bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Chemical generation of bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Dual targeting strategies with bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

The dock-and-lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

An efficient route to human bispecific IgG.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Macromolecular modeling with rosetta

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Improving target cell specificity using a novel monovalent bispecific IgG design

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Affinity and avidity in antibody-based tumor targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Converging free energy estimates: MM-PB(GB)SA studies on the protein-protein complex Ras-Raf.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Comparison between computational alanine scanning and per-residue binding free energy decomposition for protein-protein association using MM-GBSA: application to the TCR-p-MHC complex

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Automatic protein design with all atom force-fields by exact and heuristic optimization

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

CHARMM: the biomolecular simulation program

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

All-atom empirical potential for molecular modeling and dynamics studies of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Cassette baculovirus vectors for the production of chimeric, humanized, or human antibodies in insect cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Lepidopteran cells, an alternative for the production of recombinant antibodies?

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Engineering the baculovirus genome to produce galactosylated antibodies in lepidopteran cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Mapping the paratope of anti-CD4 recombinant Fab 13B8.2 by combining parallel peptide synthesis and site-directed mutagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

A modular IgG-scFv bispecific antibody topology

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-dr

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501592

21 January 2018

Identifiers

DOI

10.4049/JIMMUNOL.1501592

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921308%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference